Delcath Systems is a commercial-stage interventional oncology company developing and providing liver-directed therapies for primary and metastatic liver cancers. Its Hepatic Delivery System uses vascular isolation, focused drug delivery and filtration to administer high-dose treatment directly to the liver, with HEPZATO KIT™ marketed in the United States and CHEMOSAT® in Europe. The company’s clinical work began with uveal melanoma and is expanding into other liver-dominant cancers.
NuVue Therapeutics, IncNuVue Therapeutics, Inc. is a medical device, diagnostics, and drug delivery company with an initial focus on accurate diagnosis and targeted treatment of liver, pancreatic, and other hard-to-treat soft-tissue cancers. The company designs diagnostic products to give a bright, clear image of biopsy needles in real-time during procedures and to accurately mark sites for further imaging and/or biopsies. It also designs therapeutic products to avoid the toxic effects of systemic chemotherapy by providing targeted delivery of free and encapsulated drugs and thermal effects directly into tumors.FAIRFAX, VA
NovocureNovocure grew from Professor Yoram Palti’s basement laboratory in Haifa, where he began exploring electric fields as a way to target cancer cells in 2000. Today, the international oncology company develops and commercializes Tumor Treating Fields therapy for patients facing some of the most aggressive solid tumors, while continuing research into wider applications.WAYNE, PA
Duo OncologyFounded by nanoparticle and drug-delivery researchers, Pittsburgh-based Duo Oncology is a clinical-stage biotechnology company developing tumor-activated medicines for cancer treatment. Its lead program, DUO-207, is designed to simplify chemotherapy by concentrating drug activity in tumors while reducing exposure in healthy tissue.PITTSBURGH, PA
Modulation TherapeuticsFounded in 2011 as a Moffitt Cancer Research Center spinoff, Modulation Therapeutics is a Morgantown clinical-stage biotechnology company developing therapies for aggressive solid-tumor cancers and liver disease. Its research team combines targeted alpha radiotherapy with peptide and small-molecule drug development, including a therapy for metastatic melanoma that has received FDA Orphan Drug and Fast Track designations. The privately held company moved its primary operations to West Virginia in 2016 and works with West Virginia University researchers to advance its pipeline toward clinical use.MORGANTOWN, WV